These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20189727)

  • 1. Low-grade adenosquamous carcinoma of the breast--A case report with a BRCA1 germline mutation.
    Noël JC; Buxant F; Engohan-Aloghe C
    Pathol Res Pract; 2010 Jul; 206(7):511-3. PubMed ID: 20189727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.
    Armes JE; Egan AJ; Southey MC; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
    Cancer; 1998 Dec; 83(11):2335-45. PubMed ID: 9840533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
    van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
    J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
    Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
    Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
    Quenneville LA; Phillips KA; Ozcelik H; Parkes RK; Knight JA; Goodwin PJ; Andrulis IL; O'Malley FP
    Cancer; 2002 Nov; 95(10):2068-75. PubMed ID: 12412159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pathology of low-grade adenosquamous carcinoma of the breast. An immunohistochemical study.
    Drudis T; Arroyo C; Van Hoeven K; Cordon-Cardo C; Rosen PP
    Pathol Annu; 1994; 29 ( Pt 2)():181-97. PubMed ID: 7936747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
    Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
    Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A deleterious BRCA1 mutation in a young Pakistani woman with metaplastic breast carcinoma.
    Rashid MU; Shah MA; Azhar R; Syed AA; Amin A; Hamann U
    Pathol Res Pract; 2011 Sep; 207(9):583-6. PubMed ID: 21723046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
    Robson M; Svahn T; McCormick B; Borgen P; Hudis CA; Norton L; Offit K
    Cancer; 2005 Jan; 103(1):44-51. PubMed ID: 15558796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentric glioblastoma multiforme in a patient with BRCA-1 invasive breast cancer.
    Elmariah SB; Huse J; Mason B; Leroux P; Lustig RA
    Breast J; 2006; 12(5):470-4. PubMed ID: 16958968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
    Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
    Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status.
    Fishman A; Dekel E; Chetrit A; Lerner-Geva L; Bar-Am A; Beck D; Beller U; Ben-Baruch G; Piura B; Friedman E; Struewing JP; Modan B
    Gynecol Oncol; 2000 Oct; 79(1):74-8. PubMed ID: 11006035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-grade adenosquamous carcinoma of the breast.
    Soo K; Tan PH
    J Clin Pathol; 2013 Jun; 66(6):506-11. PubMed ID: 23268316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer.
    Breuer A; Kandel M; Fisseler-Eckhoff A; Sutter C; Schwaab E; Lück HJ; du Bois A
    Onkologie; 2007 Jun; 30(6):316-8. PubMed ID: 17551255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening.
    Palomba G; Pisano M; Cossu A; Budroni M; Dedola MF; Farris A; Contu A; Baldinu P; Tanda F; Palmieri G
    Cancer; 2005 Sep; 104(6):1172-9. PubMed ID: 16047344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
    Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
    Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.